drugset / Trial / NCT02961660

A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir

NCT02961660

Phase 1 Completed 16 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelOther

Summary

The main purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of odalasvir (ODV) in participants with severe renal impairment and compare with the PK in matched participants with normal renal function.

Timeline

Start
2016-11-09
Primary completion
2018-04-09
Completion
2018-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Odalasvir Small molecule 25 mg Oral